Cargando…

Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis

Interleukin (IL)-33 has been recently reported to be strongly pro-fibrogenic in various models of liver disease. Our aim was to study the role of endogenous IL-33 in a diet-induced model of steatohepatitis. IL-33 deficient mice and wild type (WT) littermates received a high-fat diet (HFD), or a stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasseur, Philippe, Dion, Sarah, Filliol, Aveline, Genet, Valentine, Lucas-Clerc, Catherine, Jean-Philippe, Girard, Silvain, Christine, Lecron, Jean-Claude, Piquet-Pellorce, Claire, Samson, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564708/
https://www.ncbi.nlm.nih.gov/pubmed/28611297
http://dx.doi.org/10.18632/oncotarget.18335
_version_ 1783258284611862528
author Vasseur, Philippe
Dion, Sarah
Filliol, Aveline
Genet, Valentine
Lucas-Clerc, Catherine
Jean-Philippe, Girard
Silvain, Christine
Lecron, Jean-Claude
Piquet-Pellorce, Claire
Samson, Michel
author_facet Vasseur, Philippe
Dion, Sarah
Filliol, Aveline
Genet, Valentine
Lucas-Clerc, Catherine
Jean-Philippe, Girard
Silvain, Christine
Lecron, Jean-Claude
Piquet-Pellorce, Claire
Samson, Michel
author_sort Vasseur, Philippe
collection PubMed
description Interleukin (IL)-33 has been recently reported to be strongly pro-fibrogenic in various models of liver disease. Our aim was to study the role of endogenous IL-33 in a diet-induced model of steatohepatitis. IL-33 deficient mice and wild type (WT) littermates received a high-fat diet (HFD), or a standard diet for 12 weeks. The HFD-induced steatohepatitis was associated with an upregulation of IL-33 transcripts and protein. An insulin tolerance test revealed lower systemic insulin sensitivity in IL-33-/—HFD mice than in WT-HFD mice. Nevertheless, IL-33 deficiency did not affect the severity of liver inflammation by histological and transcriptomic analyses, nor the quantity of liver fibrosis. Livers from HFD mice had more myeloid populations, markedly fewer NKT cells and higher proportion of ST2+ Treg cells and ST2+ type 2 innate lymphoid cells (ILC2), all unaffected by IL-33 deficiency. In conclusion, deficiency of endogenous IL-33 does not affect the evolution of experimental diet-induced steatohepatitis towards liver fibrosis.
format Online
Article
Text
id pubmed-5564708
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55647082017-08-23 Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis Vasseur, Philippe Dion, Sarah Filliol, Aveline Genet, Valentine Lucas-Clerc, Catherine Jean-Philippe, Girard Silvain, Christine Lecron, Jean-Claude Piquet-Pellorce, Claire Samson, Michel Oncotarget Priority Research Paper Interleukin (IL)-33 has been recently reported to be strongly pro-fibrogenic in various models of liver disease. Our aim was to study the role of endogenous IL-33 in a diet-induced model of steatohepatitis. IL-33 deficient mice and wild type (WT) littermates received a high-fat diet (HFD), or a standard diet for 12 weeks. The HFD-induced steatohepatitis was associated with an upregulation of IL-33 transcripts and protein. An insulin tolerance test revealed lower systemic insulin sensitivity in IL-33-/—HFD mice than in WT-HFD mice. Nevertheless, IL-33 deficiency did not affect the severity of liver inflammation by histological and transcriptomic analyses, nor the quantity of liver fibrosis. Livers from HFD mice had more myeloid populations, markedly fewer NKT cells and higher proportion of ST2+ Treg cells and ST2+ type 2 innate lymphoid cells (ILC2), all unaffected by IL-33 deficiency. In conclusion, deficiency of endogenous IL-33 does not affect the evolution of experimental diet-induced steatohepatitis towards liver fibrosis. Impact Journals LLC 2017-06-01 /pmc/articles/PMC5564708/ /pubmed/28611297 http://dx.doi.org/10.18632/oncotarget.18335 Text en Copyright: © 2017 Vasseur et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Priority Research Paper
Vasseur, Philippe
Dion, Sarah
Filliol, Aveline
Genet, Valentine
Lucas-Clerc, Catherine
Jean-Philippe, Girard
Silvain, Christine
Lecron, Jean-Claude
Piquet-Pellorce, Claire
Samson, Michel
Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title_full Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title_fullStr Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title_full_unstemmed Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title_short Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis
title_sort endogenous il-33 has no effect on the progression of fibrosis during experimental steatohepatitis
topic Priority Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564708/
https://www.ncbi.nlm.nih.gov/pubmed/28611297
http://dx.doi.org/10.18632/oncotarget.18335
work_keys_str_mv AT vasseurphilippe endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT dionsarah endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT filliolaveline endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT genetvalentine endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT lucasclerccatherine endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT jeanphilippegirard endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT silvainchristine endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT lecronjeanclaude endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT piquetpellorceclaire endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis
AT samsonmichel endogenousil33hasnoeffectontheprogressionoffibrosisduringexperimentalsteatohepatitis